$Roivant Sciences (ROIV.US)$ shall easily beat the 2023 Q2 e...

70794700 commented on a stock · Aug 11, 2023 01:25

$Roivant Sciences (ROIV.US)$ shall easily beat the 2023 Q2 estimate as its VTAMA Leads the Other Branded Topicals in Weekly TRx in Q2 already (see below). More important, investors may be more interested in its business update about potential deals from the next Monday earnings meeting.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

20K Views

Comment

70794700

Followers

Following

Visitors